Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
 2016 World Congress - EconoTimes)
BURLINGTON, Mass., April 01, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of its lead drug candidate Zilretta (also known as FX006) at the Osteoarthritis Research Society International (OARSI) 2016 World Congress at the RAI Amsterdam Convention Center in Amsterdam, The Netherlands, on Saturday, April 2 at 2:00 p.m. CET/9:00 a.m. EDT.
The presentation will be part of Concurrent Session 9 - OA Treatment - Structure and Pain with abstract presentations. The title of the scientific abstract is “Sustained and Profound Analgesic Benefits in People with Osteoarthritis of the Knee Using FX006, an Intra-articular Extended-Release Formulation of Triamcinolone Acetonide.”
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T: 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
